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Abstract
Objectives
To investigate contrast-enhanced ultrasound (CEUS) with VEGFR2-targeted microbubbles
for monitoring therapy effects of regorafenib on experimental colon carcinomas in rats with
correlation to dynamic contrast-enhanced MRI (DCE-MRI) and immunohistochemistry.
Materials and Methods
Human colorectal adenocarcinoma xenografts (HT-29) were implanted subcutaneously in n
= 21 (n = 11 therapy group; n = 10 control group) female athymic nude rats (Hsd: RH-
Foxn1rnu). Animals were imaged at baseline and after a one-week daily treatment with
regorafenib or a placebo (10 mg/kg bodyweight), using CEUS with VEGFR2-targeted micro-
bubbles and DCE-MRI. In CEUS tumor perfusion was assessed during an early vascular
phase (wash-in area under the curve = WiAUC) and VEGFR2-specific binding during a late
molecular phase (signal intensity after 8 (SI8min) and 10 minutes (SI10min)), using a conven-
tional 15L8 linear transducer (transmit frequency 7 MHz, dynamic range 80 dB, depth 25
mm). In DCE-MRI functional parameters plasma flow (PF) and plasma volume (PV) were
quantified. For validation purposes, CEUS parameters were correlated with DCE-MRI
parameters and immunohistochemical VEGFR2, CD31, Ki-67 and TUNEL stainings.
Results
CEUS perfusion parameter WiAUC decreased significantly (116,989 ± 77,048 a.u. to
30,076 ± 27,095a.u.; p = 0.005) under therapy with no significant changes (133,932 ±
65,960 a.u. to 84,316 ± 74,144 a.u.; p = 0.093) in the control group. In the therapy group, the
amount of bound microbubbles in the late phase was significantly lower in the therapy than
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in the control group on day 7 (SI8min: 283 ± 191 vs. 802 ± 460 a.u.; p = 0.006); SI10min: 226 ±
149 vs. 645 ± 461 a.u.; p = 0.009). PF and PV decreased significantly (PF: 147 ± 58 mL/100
mL/min to 71 ± 15 mL/100 mL/min; p = 0.003; PV: 13 ± 3% to 9 ± 4%; p = 0.040) in the ther-
apy group. Immunohistochemistry revealed significantly fewer VEGFR2 (7.2 ± 1.8 vs. 17.8
± 4.6; p < 0.001), CD31 (8.1 ± 3.0 vs. 20.8 ± 5.7; p < 0.001) and Ki-67 (318.7 ± 94.0 vs.
468.0 ± 133.8; p = 0.004) and significantly more TUNEL (672.7 ± 194.0 vs. 357.6 ± 192.0; p
= 0.003) positive cells in the therapy group. CEUS parameters showed significant (p < 0.05)
correlations to DCE-MRI parameters and immunohistochemistry.
Conclusions
CEUS with VEGFR2-targeted microbubbles allowed for monitoring regorafenib functional
and molecular therapy effects on experimental colorectal adenocarcinomas with a signifi-
cant decline of CEUS and DCE-MRI perfusion parameters as well as a significant reduction
of specifically bound microbubbles under therapy, consistent with a reduced expression of
VEGFR2.
Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, as well as one of the
most deadly. More than 1,200,000 people are diagnosed annually with CRC, and more than
600,000 die from CRC per year [1]. The World Health Organization (WHO) estimates an
increase of 77% in the number of newly diagnosed cases of CRC and an increase of 80% in
deaths from CRC by 2030 [2]. Angiogenesis has been demonstrated to play a pivotal role in
CRC and overexpression of VEGF and high vascular density in primary CRCs are associated
with an increased risk of tumor recurrence and the formation of metastases [1]. Regorafenib is
an oral multi tyrosine kinase inhibitor that showed anti-angiogenic and anti-proliferative
effects in vivo in several experimental tumor models, like breast cancer, renal cell carcinoma
and glioblastoma [3]. Regorafenib has demonstrated a significant improvement in overall sur-
vival in a phase III study in patients with metastatic CRC who failed previous therapies [1]. It
has subsequently become the first approved treatment for this indication by the US Food and
Drug Administration (FDA) and European Medical Agency (EMA) [1,4,5].
While anti-angiogenic, not primarily cytotoxic tumor therapeutics such as regorafenib have
been shown to exhibit significant effects on tumor angiogenesis and metabolism, only subtle
effects were observed on tumor size and morphology, particularly in the first phase following
therapy initiation [3,6]. In this context, approved methods of monitoring primarily cytotoxic
cancer therapies, such as the morphology-based Response Evaluation Criteria in Solid Tumors
(RECIST), are not adequately sensitive for a reliable monitoring of the early therapeutic effects
of molecular anti-angiogenic therapeutics [3,6–8]. Alternatively, functional and molecular
imaging biomarkers assessed by multiparametric imaging methods such as contrast-enhanced
ultrasound (CEUS) may provide a sensitive tool for an early and reliable therapy monitoring
of molecular, anti-angiogenic drugs. Multiparametric CEUS with targeted microbubbles (MB)
can characterize morphological, functional and molecular parameters of tumor pathophysiol-
ogy from its earliest stages [9–16]. Preclinical and clinical studies demonstrated the feasibility
of functional and molecular CEUS imaging with VEGFR2 (vascular endothelial growth factor
receptor 2) targeted MB in monitoring therapy response to anti-angiogenic treatment in
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different tumor entities [11,17–21], as VEGF is one of the most potent growth factors of endo-
thelial cells and a main regulator of angiogenesis [22–24]. Following intravenous injection, in
a first early phase tumor perfusion can be quantitatively evaluated by the assessment of various
parameters of tissue microcirculation. In a second, late phase, targeted MB bound to tumor
vascular endothelial cells, overexpressing VEGFR2 as molecular markers of angiogenesis,
allow for the non-invasive visualization of VEGF receptor 2 expression in vivo [13,21]. Thereby
CEUS with BR55 may be able to provide combined functional and molecular imaging bio-
markers for the non-invasive assessment of tumor angiogenesis and therapy response of the
investigated colon cancer xenografts under regorafenib therapy.
The hypothesis of this study is that CEUS with VEGFR2-targeted microbubbles allows for
functional and molecular in vivo monitoring of regorafenib therapy effects in colorectal adeno-
carcinoma xenografts in rats. The purpose of this project was to investigate whether the
acquired functional CEUS parameters of tumor microcirculation and the molecular CEUS
parameters of VEGFR2-specific binding can be applied as non-invasive imaging biomarkers of
therapy response and correlate it with DCE-MRI parameters of tumor microcirculation, to
acquire a composite functional and molecular biomarker panel with complementary informa-
tion of tumor angiogenesis, validated by immunohistochemistry as standard of reference.
Materials and Methods
Animal model and experimental protocol
This study was conducted in accordance with the guidelines for the care and use of laboratory
animals of the German Federal Ministry of Food and Agriculture. The protocol was approved
by the Committee for Animal Research of the Government of Upper Bavaria (Gz.55.2-1-54-
2532-178-13). Human colorectal adenocarcinoma cells HT-29 (ATCC HTB-38, Manassas,
VA) were resuspended in a total volume of 0.5 mL as a 1:1 mixture of phosphate buffered
saline (PBS pH 7.4; GIBCO Life Technologies, Darmstadt, Germany) and Matrigel1 (BD Bio-
sciences, San Jose, CA). 3 x 106 cells per animal were injected subcutaneously into the left
abdominal flank of a total of n = 21 (7–8 weeks old) female athymic nude rats (Hsd:
RH-Foxn1rnu, Harlan Laboratories Inc., Indianapolis, IN). Tumor growth was assessed by daily
caliper measurements in two dimensions. When subcutaneous tumor xenografts reached ade-
quate size, animals were randomly assigned to either the therapy (n = 11) or to the control
group (n = 10). For imaging, rats were anesthetized by continuous inhalation of isoflurane
(2.5% in pure oxygen, 2 L/min) and placed on a heating pad to maintain physiological body
temperature for the whole examinations. A multimodality imaging protocol with CEUS and
subsequent DCE-MRI examination was performed on day 0 (baseline) and on day 7 (follow-
up). Animals were treated daily with the multityrosine kinase inhibitor regorafenib (therapy
group; 10 mg/kg body weight formulated in a solution 42.5/42.5/15 of polypropylen glycol/
PEG400/pluronic F68 + 20% aqua, Bayer HealthCare, Leverkusen, Germany) or placebo (con-
trol group; volume equivalent applications of regorafenib solvent cremophor/ethanol) from
day 1 to day 6 via gastric gavage using a dedicated 16-gauge curved buttoned cannula. After
follow-up measurements on day 7, animals were euthanized, tumors explanted and fixed in
formalin as well as preserved by cryoconservation for immunohistochemical stainings (see
Fig 1).
CEUS imaging
CEUS imaging was performed on a clinical ultrasound system (Acuson Sequoia 512, Siemens,
Erlangen, Germany), using a conventional 15L8 linear transducer, fixed on a mechanical sup-
port to maintain the same imaging position in plane over time and maximize reproducibility
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(transmit frequency 7 MHz, dynamic range 80 dB, depth 25 mm and time-gain compensation,
acoustic focus placed at the largest tumor cross section) [9]. Tumors were imaged in their long
axis at baseline (day 0) and follow-up (day 7). Anesthetized rats were fixed in side position and
ultrasound coupling gel was applied onto shaved skin. First a B-mode scan of each tumor was
performed to visualize subcutaneous tumor expansion. Afterwards cadence pulse sequencing
mode (CPS) was set at low acoustic power (mechanical index (MI) = 0.16) to limit the amount
of MB destruction. Video clips acquisition was initiated immediately before injection of BR55,
continued during the first minute and afterwards minute-by-minute up to 10 minutes after
contrast injection (frame rate 16 Hz), measuring wash-in and wash-out of the MB in the tumor.
VEGFR2-specific binding was assessed at 8 and 10 minutes after BR55 injection, when circulat-
ing MB disappeared from the general circulation but the tumor tissue was still highlighted, indi-
cating specific accumulation of targeted MB on VEGFR2-expressing endothelium.
Data postprocessing
CEUS data were post-processed using dedicated software on an external workstation with
Vuebox1 (Bracco Suisse SA, Geneva, Switzerland) by drawing a region of interest (ROI) into a
highly perfused region of the vital outer rim of the tumor. This software is designed to quantify
contrast enhancement within the ROI, expressed as relative echo-power values proportional to
MB concentration and assessed in arbitrary units (a.u.) [11] [9,13] (see Fig 2). Target parame-
ters were wash-in area under the curve (WiAUC) in the early vascular phase, to provide infor-
mation about blood flow and volume [16,25], as well as measured signal intensity after 8
minutes (SI8min) and 10 minutes (SI10min) p.i., as surrogate parameters of VEGFR2-specific
binding of MB in the late molecular phase.
Microbubbles
BR55 (Bracco Suisse SA, Geneva, Switzerland) is an experimental intravenous ultrasound con-
trast agent comprising VEGFR2-specific targeted MB. The VEGFR2-binding lipopeptide was
prepared by conjugation of a heterodimer peptide to the amino group of DSPE-PEG2000-NH2
and incorporated into the phospholipid-based MB formulation. The resulting product (BR55)
is a lyophilisate in a septum-sealed vial. The gas phase in the vial is a mixture of perfluorobu-
tane and nitrogen [9,12,26]. Before use BR55 has to be reconstituted by injection of 2 mL of a
5% glucose solution through the septum of the vial. After dissolution, the resulting MB suspen-
sion is ready for use. Mean diameter of BR55 MB is 1.5 μm with a mean concentration of 2 x
109 MB per mL. The number of lipopeptide molecules per MB is approximately 4 x 105 [9,19].
Circulation time of BR55 is nearly 4 minutes [20]. BR55 was administrated to each rat at a
dose of 50 μL followed by a 150 μL saline bolus by standardized manual intravenous bolus
injection through a tail vein catheter.
Fig 1. Timeline of the experimental set-up from tumor cell implantation to tumor explantation with
immunohistochemical analysis.
doi:10.1371/journal.pone.0169323.g001
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Multiparametric MRI protocol
MRI was performed on a clinical 3 Tesla MRI scanner (Magnetom Skyra, Siemens Healthcare,
Erlangen, Germany) with the anesthetized rats in supine position using a four-channel small
flex coil (Siemens Healthcare, Erlangen, Germany). For the assessment of tumor morphology,
T2-weighted MR images were acquired using a 2D Turbo Spin Echo sequence (TR/TE: 5470/
91ms) with 0.3 x 0.3 mm in-plane resolution resulting in a matrix size of 192 x 192 and slice
thickness of 1.5 mm. Subsequently, a view-sharing sequence (TWIST, fast view-sharing gradi-
ent-recalled echo time-resolved angiography with stochastic trajectories, Siemens Healthcare,
Erlangen, Germany) with high temporal and spatial resolution [27] was started for acquisition
of the pre-contrast baseline and subsequent contrast medium bolus tracking with acquisition
of n = 300 datasets resulting in an time to acquisition of 10:13 min (Sequence details: TR/TE:
6.34/2.11 ms; flip angle 40˚; matrix size 128 x 128; field of view 50 x 50 mm2; spatial resolution,
0.39 x 0.39 x 3.0 mm3). For standardized contrast media administration, an automated bolus
of 0.1 mmol/kg body-weight of gadobutrol (Gadovist1 0.1 mmol/ml injection solution, Bayer,
Leverkusen, Germany) followed by a saline bolus of 0.5 mL was applied via tail vein catheter
using a dedicated small animal contrast media injection system (PHD2000 Series, Harvard
Apparatus, Holliston, MA).
Fig 2. ROI selection. Representative CEUS images of a rat after 7 days of regorafenib therapy with a
subcutaneous tumor xenograft (green) and blood volume parameter map with a ROI in a hypervascular vital
tumor site of the outer rim (yellow). Corresponding signal-intensity-versus-time-curves are shown below.
doi:10.1371/journal.pone.0169323.g002
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MRI data processing and kinetic analysis
Data sets were analyzed on an external workstation using a dedicated post-processing software
(PMI, Platform for Research in Medical Imaging version 0.4), written in-house in IDL 8.3
(ITT Visual Information Solutions, Boulder, CO). Corresponding to CEUS measurements, a
tissue region of interest was placed over the tumor periphery using semi-quantitative area
under the curve (AUC) maps [28]. Tumor periphery was defined as the outer rim of the tumor
(3 mm) as a representative region of viable tumor tissue which is less affected by elevated inter-
stitial pressure and necrosis compared to the tumor center [29]. An additional blood ROI was
drawn into the lumen of the intrahepatic part of the inferior vena cava in order to gain an arte-
rial input function (AIF). Signal-intensity-versus-time-curves were extracted for the tumor tis-
sue ROI and the AIF. Tracer concentrations were approximated in accordance to relative
enhancement S/S0-1 (S is signal intensity; S0 is signal intensity prior to arrival of the contrast
agent). A two-compartment exchange model [30,31] was fitted to the MRI data and two inde-
pendent quantitative parameters were selected: tumor plasma flow PF (mL/100mL/min), as a
parameter of tumor perfusion, and tumor plasma volume PV (mL/100mL = %), as a parameter
of tumor vascularity.
Immunohistochemistry
The formaldehyde-fixed and paraffin-embedded tumor tissue was stained with regard to the
following aspects of tumor pathophysiology: tumor necrosis (H&E), microvascular density
(CD31), tumor cell proliferation (Ki-67), tumor apoptosis (TUNEL) and VEGFR2 expression.
Tissue sections were dewaxed and rehydrated following standard procedures including pre-
heating at 60˚C and washing in xylene substitute (Neo-Clear1, Merck Millipore, Darmstadt,
Germany) with rehydration in a graded series of ethanol (100%, 96%, 90% and 70% ethanol)
followed by double distilled water. Afterwards dedicated staining procedures were initiated.
Hematoxylin and eosin (H&E). For the assessment of necrotic tumor areas H&E stain-
ings were performed. Paraffin was removed and tumor tissue sections were incubated in
Mayer´s hemalum solution (Merck Millipore, Darmstadt, Germany) for 5 minutes and purged
by distilled water. Subsequently tissue sections were incubated for 10 minutes under running
water and purged again briefly by distilled water, stained in eosin solution for a few seconds
and dehydrated in a graded series of ethanol (70%, 90%, 96% and 100% ethanol). Afterwards
the tissue sections were incubated for 5 minutes in NeoClear1 (Merck Millipore, Darmstadt,
Germany) twice. Finally the sections were embedded with EuKitt1 (Sigma-Aldrich, St. Louis,
MO). Results were quantified as the percentage of necrotic tissue fraction in 10 random fields
at 200x magnification.
CD31. For immunohistochemical assessment of tumor microvascular density, tumor sec-
tions were incubated with a polyclonal rabbit anti-CD31 primary antibody (Abcam ab28364
1:50, Cambridge, United Kingdom) overnight. Further work-up of tissue samples was per-
formed using the EnVision+ System HRP (AEC) (DAKO Diagnostika, Hamburg, Germany)
according to the manufacturer´s instruction. Counterstaining was performed using Mayer´s
hemalum (Merck Millipore, Darmstadt, Germany) and slides were covered with Kaiser´s
Glycerin Gelatine (Merck Millipore, Darmstadt, Germany). Tumor microvessels were quanti-
fied as the average number of endothelial cells in 10 random fields at 200x magnification [32].
Ki-67. Ki-67-specific monoclonal rabbit anti-human antibody (SP6, Abcam ab16667
1:100, Cambridge, United Kingdom) was used to quantify tumor cell proliferation. The tissue
was demasked in 1 x citrate buffer (pH = 6.0) using microwave irradiation at 600 W. After
washing the slides in ddH2O and TBS-Tween (0.05%) the multi-step kit EnVision+ System
HRP (DAB) (DAKO Diagnostika, Hamburg, Germany) was used for the staining following
CEUS with BR55 and DCE-MRI Imaging Biomarkers for Regorafenib Therapy Monitoring
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the manufacturer’s instructions. Counterstaining was performed using Mayer´s hemalum
(Merck Millipore, Darmstadt, Germany) and slides were covered with Kaiser´s Glycerin Gela-
tine (Merck Millipore, Darmstadt, Germany). Results were quantified as the average number
of proliferating cells in 10 random fields at 200x magnification.
TUNEL. For the quantification of apoptotic cells Terminal deoxynucleotidyl transferase–
mediated nick end labeling (TUNEL) staining was performed with a commercially available
apoptosis detection kit (In Situ Cell Death Detection Kit, Roche Diagnostics AG, Risch, Swit-
zerland) according to the manufacturer’s instructions. Tissue samples were subsequently ana-
lyzed using fluorescence microscopy with a standard fluorescent filter set at 520 ± 20 nm.
Results were expressed as the average number of apoptotic cells in 10 random fields at 200×
magnification (cells per high-power field).
VEGFR2. The expression of VEGFR2 was analyzed using a VEGFR2-specific monoclonal
rabbit anti-human antibody (1:50; Cell Signalling, Cambridge, UK). Following standard proce-
dures, tissue samples were dewaxed, rehydrated and subsequently demasked in target-retrieval
solution (DAKO, Hamburg, Germany) using microwave irradiation at 600 W. After overnight
incubation with the primary antibody, tissue samples were further processed using the EnVi-
sion+ System HRP (DAB) (DAKO Diagnostika, Hamburg, Germany). VEGFR2-positive
stained tumor vessels were quantified as the number in 10 random high-power fields at a mag-
nification of 200x.
Statistical analysis
Continuous variables are presented as means with standard deviations (mean ± SD). For inter-
group comparisons of CEUS parameters, MRI perfusion parameters and immunohistochemi-
cal values between the treatment and the control group, the Mann-Whitney-U-test was used.
For intragroup comparisons of CEUS and MRI perfusion parameters between baseline (day 0)
and follow-up (day 7) a Wilcoxon-signed-rank test was applied. Correlations between CEUS
and MRI parameters as well as between CEUS, MRI and immunohistochemistry were evalu-
ated by Spearman’s rank correlation coefficients (Spearmans rho = ρ). P-values < 0.05 were
considered statistically significant. All analyses were performed with a dedicated statistics soft-
ware (SPSS Version 23 for Microsoft Windows, IBM, Armonk, NY).
Results
The experimental protocol, including multimodality imaging with CEUS and DCE-MRI, was
successfully completed in n = 17 animals. In n = 3 animals the ultrasound and in n = 1 animal
the MRI measurements could not be accomplished due to technical issues. N = 1 animal of the
control group had to be excluded due to anesthesia complications. Animals were assigned ran-
domly to either the therapy or the control group with no significant differences (p> 0.05) in
tumor size as well as in CEUS and MRI values at baseline.
Tumor size
Tumor size was assessed by volumetric MRI measurements at baseline and follow-up. There
were no significant differences (p> 0.05) in mean tumor sizes between the therapy and the
control group on day 0 (524 ± 184 mm3 vs. 571 ± 289 mm3) and on day 7 (531 ± 352 mm3 vs.
651 ± 311 mm3), as well as no significant changes (p> 0.05) in tumor growth between day 0
and day 7 in the therapy (from 524 ± 184 mm3 to 531 ± 352 mm3) or in the control group
(from 571 ± 289 mm3 to 651 ± 311 mm3) (see S1 Table).
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CEUS
In CEUS with BR55, functional parameters of tumor microcirculation were assessed during an
early vascular phase and VEGFR2-specific binding of the MB during a late molecular phase up
to 10 min p.i. (see Fig 3).
In the therapy group a significant decrease of tumor microcirculation was observed follow-
ing the one-week treatment course with regorafenib, assessed by a significant decline of
WiAUC from 116,989 ± 77,048 a.u. on day 0 to 30,076 ± 27,095 a.u. on day 7 (p = 0.005). In
the control group no significant changes (p = 0.093) in WiAUC (from 133,932 ± 65,960 a.u. on
day 0 to 84,316 ± 74,144 a.u. on day 7) were noted. Moreover there were significantly lower
values of WiAUC (p = 0.009) in the therapy than in control group on day 7 (see Fig 4 and
Table 1).
In the late molecular phase, a significant decline in tumor signal intensity between baseline
and follow-up was observed in the therapy group (SI8min: from 2,781 ± 1,816 to 283 ± 191 a.u.,
p = 0.005; SI10min: from 2,412 ± 1,657 to 226 ± 149 a.u., p = 0.005) and in the control group
(SI8min: from 3,659 ± 2,588 to 802 ± 460 a.u., p = 0.012; SI10min: from 3,164 ± 2,283 to
645 ± 461 a.u., p = 0.012). However, significantly lower SI8min (283 ± 191 vs. 802 ± 460 a.u.,
p = 0.0062) and SI10min (226 ± 149 vs. 645 ± 461 a.u., p = 0.009) values were detected in the
therapy than in the control group on day 7 (see Fig 5 and Table 2).
DCE-MRI
The two-compartment model fit the data well in all experiments. In the regorafenib-treated
therapy group mean PF declined significantly (p = 0.003) from 147 ± 58 mL/100 mL/min at
baseline to 71 ± 15 mL/100 mL/min at follow-up. In the control group no significant
(p = 0.515) changes were observed between day 0 and day 7 (from 108 ± 24 to 113 ± 31 mL/
100 mL/min). Individual values showed a unidirectional decline of tumor perfusion in the
therapy group and a heterogeneous development in the control group. Mean PV decreased sig-
nificantly (p = 0.040) over the one-week treatment course from 13 ± 3% at baseline to 9 ± 4%
at follow-up. In the control group no significant change (p = 0.514) of mean plasma volume
was observed between baseline and follow-up (from 14 ± 6 to 16 ± 8%). Additionally signifi-
cantly lower values of PF (71 ± 15 vs. 113 ± 31 mL/100 mL/min, p = 0.002) and PV (9 ± 4 vs.
16 ± 8%, p = 0.012) were measured in treated than in non-treated animals on day 7 (see
Table 3).
Immunohistochemistry
Significantly (p< 0.05) more necrotic tumor tissue was observed in regorafenib treated ani-
mals than in the placebo group (58.6 ± 14.2% vs. 18.3 ± 6.4%). Significant anti-angiogenic
effects of regorafenib were observed in the investigated colon carcinoma xenografts with a sig-
nificantly lower (p< 0.001) microvascular density in regorafenib-treated than in non-treated
animals (8.1 ± 3.0 vs. 20.8 ± 5.7), quantified by CD31 stainings. Significant anti-proliferative
effects of regorafenib were noted in Ki-67 stainings with a significantly lower (p = 0.004) num-
ber of proliferating cells in the therapy than in the control group (318.7 ± 94.0 vs.
468.0 ± 133.8). Pro-apoptotic effects of regorafenib were quantified by TUNEL stainings with
a significantly higher (p = 0.003) number of apoptotic cells in the therapy than in the control
group (627.7 ± 194.0 vs. 357.6 ± 192.0). VEGFR2 stainings showed a significantly lower
(p< 0.001) VEGFR2 expression in regorafenib-treated than in placebo-treated animals
(7.2 ± 1.8 vs. 17.8 ± 4.6) (see Fig 6 and Table 4).
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Fig 3. Representative CEUS images of a rat with a subcutaneous tumor xenograft (white arrows) under treatment. Therapy group (red) and
control group (blue) at baseline and follow-up. Left side: early vascular phase with BR55 as a functional imaging biomarker; right side: late phase of
VEGFR2-specific binding with BR55 as a molecular imaging biomarker 8 minutes after contrast injection. Note the significant lower number of circulating
microbubbles in the early vascular phase as well as the significant lower number of bound microbubbles in the late phase at follow-up in the therapy group,
compared to baseline and compared to the control group.
doi:10.1371/journal.pone.0169323.g003
Fig 4. Column charts of WiAUC in the therapy and control group at follow-up. Note the significant difference
(p < 0.05) between the mean values of WIAUC between the therapy and the control group at the follow-up.
doi:10.1371/journal.pone.0169323.g004
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Correlations between CEUS and immunohistochemistry
CEUS perfusion parameter WiAUC showed moderate, but significant correlations to CD31 (ρ
= 0.053; p = 0.024), to Ki-67 (ρ = 0.53; p = 0.025), as well as to VEGFR2 stainings (ρ = 0.48;
p = 0.042) (see Table 5).
In the late VEGFR2-specific phase, significant moderate to good correlations between
molecular CEUS parameters and immunohistochemistry were observed: immunohistochemi-
cal VEGFR2 expression correlated significantly with SI8min (ρ = 0.66; p = 0.003) and with
SI10min (ρ = 0.62; p = 0.006) (see Fig 7). Additionally microvascular density (CD31) showed
significant moderate correlations to SI8min (ρ = 0.54; p = 0.022) and to SI10min (ρ = 0.53;
p = 0.025) (see Table 6).
Table 1. Individual functional CEUS values.
Animal No. WiAUC [a.u.]
Day 0 Day 7
THERAPY GROUP
1 n/a n/a
2 102,709 29,476
3 50,150 39,784
4 47,518 7,779
5 282,576 5,463
6 200,592 19,290
7 69,803 31,530
8 82,944 7,070
9 66,663 39,336
10 94,354 22,951
11 172,584 98,085
Mean 116,989* 30,076*/#
SD 77,048 27,095
CONTROL GROUP
12 n/a n/a
13 92,930 69,166
14 232,554 85,876
15 117,899 261,323
16 n/a n/a
17 116,438 78,529
18 53,246 23,437
19 118,856 48,542
20 102,021 49,414
21 237,511 58,243
Mean 133,932 84,316#
SD 65,960 74,144
Individual functional CEUS values of tumor microcirculation in subcutaneous human colon carcinoma
xenografts at baseline and follow-up in the therapy and in the control group. Note the significant decrease of
WiAUC between day 0 and day 7 in the therapy group as well as the significantly lower mean WiAUC values
in the therapy than in the control group at follow-up.
* significant difference (p < 0.01) between baseline and follow-up
# significant difference (p < 0.01) between therapy and control group
n/a = not available due to technical issues
doi:10.1371/journal.pone.0169323.t001
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Correlations between DCE-MRI and immunohistochemistry
Moderate, significant correlations were observed between MRI perfusion parameters and
immunohistochemistry: PF correlated significantly with CD31 (ρ = 0.62; p = 0.003), Ki-67 (ρ =
0.49; p = 0.030) and with VEGFR2 (ρ = 0.46; p = 0.042). PV correlated significantly with Ki-67
(ρ = 0.49; p = 0.030).
Correlations between CEUS and DCE-MRI parameters
A significant, moderate correlation was observed between CEUS parameter WiAUC and MRI
parameter PF (ρ = 0.51; p = 0.035).
Discussion
The present study investigated the potential of CEUS with BR55 for the non-invasive monitor-
ing of regorafenib therapy effects on experimental colorectal carcinoma xenografts in rats and
its applicability to generate functional and molecular imaging biomarkers of therapy response
correlated to DCE-MRI and validated with multiparametric immunohistochemistry. Our
results provide evidence that multiparametric CEUS with BR55 can be applied for the detec-
tion of early regorafenib therapy effects based on different functional and molecular parame-
ters of tumor pathophysiology.
CEUS: assessment of tumor microcirculation and VEGFR2-specific
imaging
Significant changes of tumor microcirculation were observed with a significant decline of
WiAUC between day 0 and day 7 under therapy. We noted no significant changes in WiAUC
in the control group, under the constraint that a mild outlier favors this result. If we exclude
Fig 5. Column charts of SI10min in the therapy and control group at follow-up. Note the significant difference
(p < 0.05) between the mean values of SI10min between the therapy and the control group at the follow-up.
doi:10.1371/journal.pone.0169323.g005
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this mild outlier, the control group would also have a significant decrease of WiAUC. Never-
theless we observedsignificantly lower values of WiAUC in the therapy group than in the con-
trol group at the follow-up, signalling the regorafenib therapy effect. This is in accordance with
Zocco et al. who applied CEUS with untargeted microbubbles to investigate patients with
advanced hepatocellular carcinoma under sorafenib therapy in a clinical study, assessing
parameters of microcirculation including AUC and observed a significant decrease of AUC
following 15 days of sorafenib therapy, associated with a longer survival and with a significant
correlation to progression free survival [33]. Differing from our study, Zocco et al. applied a
non-targeted intravascular ultrasound contrast agent, which, however, resembles BR55 in bub-
ble size and kinetics providing similar measures of tumor microcirculation and a similar
Table 2. Individual molecular CEUS values.
Animal No. SI8min [a.u.] SI10min [a.u.]
Day 0 Day 7 Day 0 Day 7
THERAPY GROUP
1 n/a n/a n/a n/a
2 2,048 533 1,794 502
3 2,012 173 1,813 118
4 1,479 175 1,257 143
5 6,471 99 5,348 84
6 5,849 188 5,642 138
7 2,640 226 2,277 181
8 1,835 166 1,549 145
9 1,867 467 1,578 365
10 2,089 157 1,749 140
11 1,515 649 1,110 433
Mean 2,781* 283*/# 2,412* 226*/#
SD 1,816 191 1,657 149
CONTROL GROUP
12 n/a n/a n/a n/a
13 4,055 996 3,562 835
14 4,695 1,667 4,695 1,528
15 9,235 592 7,858 446
16 n/a n/a n/a n/a
17 1,815 1,224 1,544 1,010
18 1,246 695 1,001 607
19 2,325 460 1,920 348
20 1,817 328 1,413 223
21 4,086 453 3,316 166
Mean 3,659** 802** 3,164** 645**/#
SD 2,588 460 2,283 461
Individual CEUS signal intensity values of VEGFR2-specific binding in the late phase at baseline and follow-up in the therapy and in the control group. Note
the significant decrease of signal intensity at 8 minutes (SI8min) and 10 minutes (SI10min) post injection between day 0 and day 7 in the therapy and the
control group. However, significantly (p < 0.01) lower mean SI8min and SI10min was observed in regorafenib-treated animals compared to the control group.
* significant difference (p < 0.01) between baseline and follow-up
** significant difference (p < 0.03) between baseline and follow-up
# significant difference (p < 0.01) between therapy and control group
n/a = not available due to technical issues
doi:10.1371/journal.pone.0169323.t002
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wash-in-phase of the MB uptake as non-targeted agents with intravascular kinetics and distri-
bution to the same tumor regions [13,34,35].
With regard to the assessment of VEGFR2 expression in the molecular late phase, on day 7
significantly lower SI8min and SI10min values were observed in the therapy group compared to
the control group at follow-up, reflecting a significantly lower number of MB bound to
VEGFR2 on the tumor endothelial surface in tumors following regorafenib therapy. This is in
accordance with Baetke et al., who showed in their study with heterotopic squamous cell carci-
noma xenografts in nude mice under anti-VEGF antibody therapy 8 minutes after BR55 MB
injection a significant lower amount of specifically bound BR55 MB in treated tumors com-
pared to the control group on day 4, day 7 and day 14 [21]. Corresponding to our results, Pysz
Table 3. Individual DCE-MRI values.
Animal No. PF [mL/100mL/min] PV [%]
Day 0 Day 7 Day 0 Day 7
THERAPY GROUP
1 140 48 9 6
2 96 79 9 3
3 114 86 10 11
4 195 63 13 10
5 213 77 10 17
6 249 86 15 11
7 130 78 12 9
8 123 64 12 8
9 81 47 13 7
9 201 90 14 5
11 78 61 20 7
Mean 147* 71*/# 13* 9*/#
SD 58 15 3 4
CONTROL GROUP
12 155 99 8 10
13 93 114 8 15
14 94 112 8 7
15 110 139 17 26
16 140 124 14 10
17 n/a n/a n/a n/a
18 107 46 24 14
19 86 156 20 12
20 102 125 15 28
21 86 100 12 21
Mean 108 113# 14 16#
SD 24 31 6 8
Individual DCE-MRI parameters of tumor microcirculation with tumor plasma flow (PF; mL/100mL/min) and
plasma volume (PV; %) at baseline and follow-up in the therapy and in the control group. Note the significant
decrease of tumor microcirculatory parameters PF and PV between day 0 and day 7 as well as the
significantly lower mean values of PF and PV in the therapy than in the control group at the follow-up.
* significant difference (p < 0.05) between baseline and follow-up
# significant difference (p < 0.03) between therapy and control group
n/a = not available due to technical issues
doi:10.1371/journal.pone.0169323.t003
CEUS with BR55 and DCE-MRI Imaging Biomarkers for Regorafenib Therapy Monitoring
PLOS ONE | DOI:10.1371/journal.pone.0169323 January 6, 2017 13 / 22
Fig 6. Representative immunohistochemical stainings. CD31 (A, B; microvascular density), Ki-67 (C, D;
cell proliferation), TUNEL (E, F; apoptosis) and VEGFR2 expression (G,H) in the therapy (left column: A, C, E,
G) and in the control group (right column: B, D, F, H). Note the significant lower (p < 0.01) microvascular
density, tumor cell proliferation and VEGFR2 expression and the significant higher (p < 0.01) apoptosis rate in
the therapy group. Scale bar in images represents 100 μm.
doi:10.1371/journal.pone.0169323.g006
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Table 4. Individual immunohistochemical values.
Animal No. HE CD31 Ki-67 TUNEL VEGFR2
THERAPY GROUP
1 66.9 7.7 286.6 345.9 6.3
2 61.9 10.2 232.3 858.3 9.5
3 62.7 10.2 349.7 613.5 8.2
4 33.7 10.1 412.1 436.4 8.2
5 70.7 4.0 265.3 739.5 5.9
6 55.0 9.7 233.8 781.4 7.5
7 57.7 9.8 330.8 936.4 5.8
8 35.2 3.7 216.8 582.1 3.3
9 50.8 3.0 289.2 574.8 7.7
10 73.1 10.4 537.3 n/a 9.1
11 76.4 9.8 352.2 858.2 7.0
Mean 58.6* 8.1* 318.7* 672.7* 7.2*
SD 14.2 3.0 94.0 194.0 1.8
CONTROL GROUP
12 21.9 30.2 338.7 597.2 16.9
13 16.8 23.5 449.6 464.6 24.6
14 18.3 19.5 300.8 390.5 16.8
15 14.3 18.8 597.9 152.8 16.0
16 22.5 27.4 370.9 480.4 20.1
17 11.8 10.5 583.5 326.8 18.8
18 8.3 22.5 414.0 34.6 22.3
19 31.6 14.3 592.5 423.6 15.3
20 18.3 21.0 352.6 570.8 7.6
21 19.0 20.3 679.5 134.9 19.4
Mean 18.3* 20.8* 468.0* 357.6* 17.8*
SD 6.4 5.7 133.8 192.0 4.6
Individual values for the investigated histological and immunohistochemical parameters of tumor necrosis (HE), tumor microvascular density (CD31), tumor
cell proliferation (Ki-67), tumor cell apoptosis (TUNEL) and VEGFR2 expression in the therapy and in the control group. Note the significantly higher
necrosis rate (%) and higher number of apoptotic cells as well as the significantly lower tumor vascularity, tumor cell proliferation and VEGFR2 expression in
the regorafenib-treated therapy group.
* significant difference (p < 0.01) between therapy and control group
n/a = not available due to technical issues
doi:10.1371/journal.pone.0169323.t004
Table 5. Correlations between functional CEUS values and immunohistochemistry.
Correlation Spearman ρ p
WiAUC/CD31 0.53* 0.024
WiAUC/Ki-67 0.53* 0.025
WiAUC/VEGFR2 0.48* 0.042
*Significant correlations between functional CEUS parameter of tumor microcirculation WiAUC and
immunohistochemical markers of tumor microvascular density (CD31), tumor cell proliferation (Ki-67) and
VEGFR2 expression.
doi:10.1371/journal.pone.0169323.t005
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et al. reported a significant difference of targeted imaging signal using CEUS and BR55 already
24h after initiation of anti-VEGF-antibody therapy in human colon cancer xenografts in mice,
which remained significantly lower in treated than in untreated animals during 5 days of
observation [10]. Differing from our findings, Pysz and colleagues only observed a significant
decrease of targeted imaging signal in treated and not in untreated animals, however using a
shorter treatment interval of only 24h.
Our observation, that SI8min and SI10min decreased significantly between day 0 and day 7
not only in the regorafenib-treated therapy but also in the untreated control group is paralleled
by findings of Baron Toaldo et al., who reported a progressive reduction of the differential tar-
geted enhancement (dTE = SI before destruction of MBs–SI after destruction of MBs) using
BR55-enhanced CEUS in sorafenib-treated as well as in untreated animals [11]. As possible
explanation for this unexpected finding Baron Toaldo and colleagues discussed the occurrence
Fig 7. Line regression analysis for the correlation between CEUS parameter of VEGFR2-specific
binding and immunohistochemical VEGFR2 expression. Note the significant correlation between the
values of SI8min and the number of VEGFR2 positive stained vessels (Spearman´s ρ = 0.66, p = 0.003) for the
therapy and the control group.
doi:10.1371/journal.pone.0169323.g007
Table 6. Correlations between molecular CEUS values and immunohistochemistry.
Correlation Spearman ρ p
SI8min/CD31 0.54* 0.022
SI10min/CD31 0.53* 0.025
SI8min/VEGFR2 0.66* 0.003
SI10min/VEGFR2 0.62* 0.006
*Significant, moderate correlations between molecular CEUS parameters of VEGFR2-specific binding
(SI8min and SI10min) and immunohistochemical CD31 and VEGFR2 expression.
doi:10.1371/journal.pone.0169323.t006
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of large necrotic areas in untreated control tumors as a result of rapid uninhibited tumor
growth lacking a correspondingly large enough vasculature with consecutively lower BR55
binding in tumors of the control group. The authors argued that the production of VEGF is
dependent on tumor cell mass and that the reduction of effective vital tumor mass in rapidly
growing tumors might be responsible for the transient reduction in vascular proliferation and
VEGFR2 expression with decreased BR55 binding [11]. Consequently, the development of
necrosis may be considered a confounding cause of the reduction of dTE also in treated
tumors. To investigate this potential confounding factor in our study, H&E stainings were per-
formed for the assessment of necrotic tumor tissue in treated and untreated tumors and
revealed significantly larger necrotic areas in the regorafenib-treated compared to the control
group. However, significant central tumor necrosis was also observed in the untreated animals
of the control group, as a potential confounding factor for the significant decrease of
VEGFR2-specific MB binding in both groups. Therefore, in contrast to the study of Baron
Toaldo et al., who quantified ROIs enclosing the whole tumor, in the present study ROIs were
selected over the vital outer rim of therapy and control tumors to avoid tumor necrosis and
areas of elevated interstitial pressure with consecutively altered contrast media kinetics with
the aim to exclude tumor necrosis as potential confounding factor for the observed reduction
of VEGFR-2 expression. The observed moderate, yet significant reduction of VEGFR-2 MB
binding in tumors of the control group between day 0 and day 7 remains therefore unclear and
warrants further investigation of the specific kinetics of VEGFR-2 targeting MB in untreated
tumors. Nonetheless, the significantly lower number of MB bound to VEGFR2 on the tumor
endothelial surface in tumors following regorafenib therapy on day 7 allowed for the reliable
identification of responding, regorafenib-treated tumors compared to the control group.
DCE-MRI validation
During a one-week treatment protocol with regorafenib, a significant decrease of tumor perfu-
sion (PF) and tumor vascularity (PV) was observed between day 0 and day 7 in the therapy
group, with no significant changes detected in the control group. These results are in accor-
dance with several preclinical and clinical studies in the literature [28,36,37]. Intraindividual
comparisons of early vascular CEUS and DCE-MRI perfusion parameters revealed only mod-
erate, but significant correlations for WiAUC (CEUS) and PF (DCE-MRI). Correlations were
possibly hampered by the circumstance that similar, but not identical parameters of tumor
microcirculation were acquired by CEUS and DCE-MRI, reflecting preferably similar but not
identical pathophysiological processes, as well as differences in scanning and slice positions.
Although the time between both examinations was kept to a minimum in our study, we have
had leveled experimental conditions with no synchronous acquisition of CEUS and DCE-MRI
parameters, that would possibly broaden concordance between CEUS and MRI parameters.
Immunohistochemical validation
Immunohistochemical analysis revealed significant anti-angiogenic, anti-proliferative and
pro-apoptotic effects of regorafenib on colorectal carcinoma xenografts, as well as a signifi-
cantly reduced expression of VEGFR2. CEUS parameter of tumor microcirculation WiAUC
in the early vascular phase showed moderate, significant correlations to immunohistochemical
CD-31, Ki-67 and VEGFR2 stainings. This is in accordance with Forsberg et al., who demon-
strated a significant correlation of histological tumor vascularity and CEUS measurements
with non-targeted ultrasound contrast media in a recent study with breast tumors, by correlat-
ing the ultrasonic fractional breast tumor vascularity (FV = number of color pixels relative to
the total number of pixels within the breast mass) and CD31 [38]. SI8min and SI10min in the late
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molecular phase, as parameters of VEGFR2-specific binding, also showed significant, moder-
ate correlations to immunohistochemical measures of VEGFR2 expression and to microvascu-
lar density (CD31). This is in accordance with Bzyl et al. who discussed in their study with two
differently aggressive breast carcinoma xenografts in mice, that the relative amount of recep-
tor-bound MBs corresponds to immunohistochemical differences in tumor microvascular
density (CD31) as well as to VEGFR2 expression concluding that BR55 reflects the VEGFR2
status in tumors and can be applied as non-invasive surrogate parameter of tumor angiogene-
sis [12]. Similarly, Baron Toaldo et al. concluded in his study in mice with HCC xenografts
under sorafenib therapy, that the investigated CEUS parameter of VEGFR2 specific binding
(dTE) on day 14 is significantly related to immunohistochemically expressed VEGFR2 levels
[11].
In consideration of the reported findings, the significant correlations to the immunohisto-
chemical standard of reference in our study support our hypothesis that the investigated
parameters of tumor microcirculation indeed reflect processes of tumor pathophysiology and
may therefore be applicable as non-invasive imaging biomarkers of therapy response to regor-
afenib. It furthermore indicates the potential of CEUS to provide non-invasive imaging bio-
markers of tumor angiogenesis [14,39–41].
Limitations
Our study results are limited in several aspects. Firstly, our study investigated only one tumor-
therapy-combination in a heterotopic xenograft model of colon cancer with only limited trans-
lational relevance to orthotopic tumor pathophysiology in humans [42]. Nevertheless other
experiments demonstrated the clinical potential of CEUS for monitoring changes in tumor
vascularisation secondary to anti-angiogenetic cancer treatments [16]. Secondly we observed
only a short period of time without determining clinical endpoints such as overall survival of
the animals, but our preclinical study was focused on novel imaging biomarkers of an early
therapy response, that allow a reliable and timely differentiation of responders from non-
responders. To validate our imaging results, several established immunohistochemical param-
eters were investigated, reflecting central and representative aspects of tumor pathophysiology
under anti-angiogenic therapy, as surrogate markers of therapy response [1] Morevover, as
mentioned before, Zocco et al. observed in patients with advanced hepatocellular carcinoma
under sorafenib therapy an association of a significant decrease of ultrasound perfusion
parameters under therapy with a longer survival and a significant correlation to progression
free survival [33]. Thirdly analysis was limited to a single, central plane of the tumor. In CEUS
as well as in DCE-MRI it is not completely avoidable that animals are scanned in slightly dif-
ferent planes at baseline and follow-up due to changes in tumor size during the treatment
course with possible influence on parameters of tumor microcirculation and VEGFR2 binding.
To minimize these differences and to maximize reproducibility we used a mechanical support
for fixing the animals and care was taken to reposition the imaging plane on the largest, central
cross section of the tumor in order to maintain similar scanning positions and slices during
each measurement [11]. In this case the use of three-dimensional CEUS would be helpful,
especially in the evaluation of heterogeneous tumors by providing a volumetric assessment of
parameters, which will allow sampling not only of a small anatomical area but a more complete
assessment of tumor vascularity [14,43,44]. Thirdly it has been demonstrated in former experi-
ments, that BR55 binds to VEGFR2 with high affinity and specificity [9,10,13]. However, no
dedicated in vivo blocking studies were performed to discriminate between endothelium- and
possible extracellular cell-bound BR55, as BR55 has an intravascular distribution profile with-
out relevant extravasation [9,10,12,20].
CEUS with BR55 and DCE-MRI Imaging Biomarkers for Regorafenib Therapy Monitoring
PLOS ONE | DOI:10.1371/journal.pone.0169323 January 6, 2017 18 / 22
Conclusion
In conclusion, our results indicate that multiparametric CEUS with VEGFR2-targeted MB
allows for monitoring functional and molecular therapy effects of regorafenib on the investi-
gated experimental colorectal adenocarcinomas in rats. Experiments revealed a significant
decline of CEUS and DCE-MRI perfusion parameters in the therapy group between baseline
and follow-up as well as a significant reduction of VEGFR2 binding MB under therapy paral-
leled by a significantly reduced expression of VEGFR2 assessed by immunohistochemistry.
CEUS with VEGFR2-targeted MB offers a comprehensive, multi-facetted and non-invasive
characterization of tumor angiogenesis. Our results provide encouraging perspectives for the
non-invasive monitoring of microvascular and molecular modifications in vivo under anti-
angiogenic therapy.
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